Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,026 | 492 | 99.0% |
| Education | $89.38 | 35 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,459 | 90 | $0 (2024) |
| Collegium Pharmaceutical, Inc. | $855.60 | 80 | $0 (2024) |
| Amgen Inc. | $819.48 | 19 | $0 (2022) |
| GRT US Holding, Inc. | $495.84 | 18 | $0 (2022) |
| Daiichi Sankyo Inc. | $388.39 | 37 | $0 (2019) |
| PFIZER INC. | $320.35 | 35 | $0 (2024) |
| Lundbeck LLC | $309.97 | 15 | $0 (2024) |
| Allergan, Inc. | $308.10 | 11 | $0 (2021) |
| SCILEX PHARMACEUTICALS INC. | $264.72 | 15 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $238.75 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,319 | 84 | ABBVIE INC. ($455.21) |
| 2023 | $1,112 | 86 | AbbVie Inc. ($347.12) |
| 2022 | $1,744 | 95 | ABBVIE INC. ($557.47) |
| 2021 | $677.36 | 34 | Amgen Inc. ($104.83) |
| 2020 | $684.74 | 31 | Allergan, Inc. ($216.39) |
| 2019 | $1,249 | 51 | Amgen Inc. ($342.56) |
| 2018 | $1,067 | 67 | Collegium Pharmaceutical, Inc. ($177.27) |
| 2017 | $1,262 | 79 | Daiichi Sankyo Inc. ($213.68) |
All Payment Transactions
527 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $8.70 | General |
| Category: Opioid Analgesic | ||||||
| 12/16/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $15.69 | General |
| Category: NEUROLOGY | ||||||
| 12/16/2024 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $11.06 | General |
| Category: PAIN | ||||||
| 12/12/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $8.47 | General |
| Category: Opioid Analgesic | ||||||
| 12/05/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $5.76 | General |
| Category: Opioid Analgesic | ||||||
| 12/02/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: PAIN | ||||||
| 11/25/2024 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $22.93 | General |
| Category: PAIN | ||||||
| 11/21/2024 | ABBVIE INC. | QULIPTA (Drug), BOTOX | Food and Beverage | In-kind items and services | $5.76 | General |
| Category: NEUROSCIENCE | ||||||
| 11/20/2024 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $6.20 | General |
| Category: PAIN | ||||||
| 11/18/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $22.05 | General |
| Category: Opioid Analgesic | ||||||
| 11/14/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $6.42 | General |
| Category: Opioid Analgesic | ||||||
| 11/04/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: NEUROSCIENCE | ||||||
| 10/28/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $13.43 | General |
| Category: NEUROLOGY | ||||||
| 10/24/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $8.92 | General |
| Category: Opioid Analgesic | ||||||
| 10/23/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $18.39 | General |
| Category: Analgesic | ||||||
| 10/22/2024 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $3.95 | General |
| Category: PAIN | ||||||
| 10/21/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $13.52 | General |
| Category: NEUROSCIENCE | ||||||
| 10/16/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: NEUROSCIENCE | ||||||
| 10/09/2024 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $10.24 | General |
| Category: PAIN | ||||||
| 10/07/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: NEUROSCIENCE | ||||||
| 10/03/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $6.51 | General |
| Category: Opioid Analgesic | ||||||
| 09/30/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $17.24 | General |
| Category: Analgesic | ||||||
| 09/23/2024 | Forte Bio-Pharma LLC | PROLATE (Drug), NALOCET, PROLATE | Food and Beverage | In-kind items and services | $24.53 | General |
| Category: PAIN | ||||||
| 09/19/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $81.02 | General |
| Category: NEUROSCIENCE | ||||||
| 09/18/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $7.28 | General |
| Category: Opioid Analgesic | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 940 | 4,141 | $675,870 | $257,562 |
| 2022 | 10 | 961 | 4,174 | $676,662 | $257,314 |
| 2021 | 10 | 840 | 2,851 | $405,361 | $167,091 |
| 2020 | 10 | 701 | 1,820 | $253,002 | $78,264 |
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 357 | 2,624 | $577,280 | $223,490 | 38.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 86 | 165 | $23,100 | $9,921 | 42.9% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 302 | 692 | $20,760 | $8,513 | 41.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 58 | 58 | $23,200 | $8,198 | 35.3% |
| 20553 | Injection of trigger points, 3 or more muscles | Office | 2023 | 39 | 75 | $16,275 | $3,019 | 18.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 23 | 24 | $6,720 | $2,969 | 44.2% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 16 | 28 | $6,160 | $1,312 | 21.3% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 22 | 170 | $850.00 | $132.85 | 15.6% |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | Office | 2023 | 37 | 305 | $1,525 | $6.23 | 0.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 343 | 2,525 | $555,500 | $216,659 | 39.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 126 | 253 | $35,420 | $13,870 | 39.2% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2022 | 277 | 745 | $22,350 | $9,185 | 41.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 47 | 47 | $18,800 | $7,406 | 39.4% |
| 20553 | Injection of trigger points, 3 or more muscles | Office | 2022 | 51 | 106 | $23,002 | $4,551 | 19.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 27 | 27 | $7,560 | $2,804 | 37.1% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 22 | 30 | $7,700 | $1,587 | 20.6% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2022 | 11 | 11 | $4,180 | $1,147 | 27.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 18 | 109 | $545.00 | $100.20 | 18.4% |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | Office | 2022 | 39 | 321 | $1,605 | $5.73 | 0.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 280 | 1,291 | $284,020 | $122,776 | 43.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 154 | 338 | $47,320 | $21,262 | 44.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 37 | 37 | $14,800 | $5,831 | 39.4% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2021 | 194 | 410 | $12,300 | $5,166 | 42.0% |
| 20553 | Injections of trigger points in 3 or more muscles | Office | 2021 | 54 | 115 | $24,955 | $4,998 | 20.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 31 | 33 | $9,240 | $4,025 | 43.6% |
About Dr. Renjini Chandra, MD
Dr. Renjini Chandra, MD is a Physical Medicine & Rehabilitation healthcare provider based in Overland Park, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/18/2005. The National Provider Identifier (NPI) number assigned to this provider is 1831181619.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Renjini Chandra, MD has received a total of $9,115 in payments from pharmaceutical and medical device companies, with $1,319 received in 2024. These payments were reported across 527 transactions from 62 companies. The most common payment nature is "Food and Beverage" ($9,026).
As a Medicare-enrolled provider, Chandra has provided services to 3,442 Medicare beneficiaries, totaling 12,986 services with total Medicare billing of $760,231. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Practice Information
- Specialty Physical Medicine & Rehabilitation
- Other Specialties Physical Medicine & Rehabilitation
- Location Overland Park, KS
- Active Since 08/18/2005
- Last Updated 10/16/2023
- Taxonomy Code 208100000X
- Entity Type Individual
- NPI Number 1831181619
Products in Payments
- UBRELVY (Drug) $1,055
- Aimovig (Biological) $790.40
- QULIPTA (Drug) $514.43
- Qutenza (Drug) $495.84
- NURTEC ODT (Drug) $344.29
- XTAMPZA (Drug) $325.28
- VYEPTI (Biological) $309.97
- Morphabond ER (Drug) $300.51
- Xtampza ER (Drug) $244.02
- RELISTOR (Drug) $221.91
- ZTLido (Drug) $209.74
- Belbuca (Drug) $207.98
- NALOCET (Drug) $195.20
- BRIXADI (Drug) $159.04
- Lucemyra/Lofexidine (Drug) $156.09
- Levorphanol (Drug) $151.56
- Seglentis (Drug) $136.18
- Nucynta (Drug) $131.86
- TROKENDI XR (Drug) $129.15
- Movantik (Drug) $129.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Physical Medicine & Rehabilitation Doctors in Overland Park
Atul Patel, M.d, M.D
Physical Medicine & Rehabilitation — Payments: $762,530
Srinivas Nalamachu, Md, MD
Physical Medicine & Rehabilitation — Payments: $695,414
Steven Simon, Md, MD
Physical Medicine & Rehabilitation — Payments: $180,356
James Sigler, Md, MD
Physical Medicine & Rehabilitation — Payments: $24,250
Dr. Lauren Neuman, Do, Mba, DO, MBA
Physical Medicine & Rehabilitation — Payments: $2,745
Deborah Ruggles, Md, MD
Physical Medicine & Rehabilitation — Payments: $2,310